Research ArticleCancer
Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β
- Yan Lan*,
- Dong Zhang,
- Chunxiao Xu,
- Kenneth W. Hance†,
- Bo Marelli,
- Jin Qi,
- Huakui Yu,
- Guozhong Qin,
- Aroop Sircar,
- Vivian M. Hernández,
- Molly H. Jenkins,
- Rachel E. Fontana,
- Amit Deshpande,
- George Locke,
- Helen Sabzevari‡,
- Laszlo Radvanyi and
- Kin-Ming Lo*
- EMD Serono Research and Development Institute Inc., Billerica, MA 01821, USA.
- ↵*Corresponding author. Email: yan.lan{at}emdserono.com (Y.L.); kinming.lo{at}emdserono.com (K.-M.L.)
↵† Present address: GlaxoSmithKline, Collegeville, PA 19426, USA.
↵‡ Present address: Intrexon Corporation, Germantown, MD 20876, USA.
See allHide authors and affiliations
Science Translational Medicine 17 Jan 2018:
Vol. 10, Issue 424, eaan5488
DOI: 10.1126/scitranslmed.aan5488
